All In Biotech

Drug Trial Radar · NCT03104595

Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer

EC-18 for Management of Chemotherapy-Induced Neutropenia in Patients With Advanced BC Receiving Low Febrile Neutropenia Risk Chemotherapy: Dose-Escalation, Open-label, Trial to Assess Safety and Tolerability of EC-18

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

28

Actual

Start

Oct 30, 2017

Primary completion

Nov 26, 2019

Study completion Dec 5, 2019

Sponsor

Sponsor type
Industry
First posted
Apr 7, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the safety and establish the dose to assess the pharmacokinetic activity following administration of EC-18 in patients with advanced breast cancer receiving low febrile neutropenia risk chemotherapy who are the candidates for second-line or higher combination therapy with doxorubicin and cyclophosphamide.

Conditions

  • Febrile Neutropenia

Interventions

  • EC-18Drug

    oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration of Grade 4 NeutropeniaTime frame: During Cycle 1 of chemotherapy (up to 21 days)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center

    Gyeonggi-do, Gyeonggi-do, South Korea

  • Yonsei University Health System Severance Hospital

    Seoul, Seoul, South Korea

  • Asan Medical Center

    Seoul, Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.